UK Votes To Leave The EU – Where Next For The Life Sciences?
This article was originally published in Clinica
Executive Summary
So that's it. After months of discussion, debate, and an ocean of statistics, claims and counter-claims, the UK has voted to leave the EU and strike out on its own. It was always going to be a close-run thing, and even on the day of the referendum itself the result seemed too close to call, even if the markets had been rallying in expectation of a Remain vote.
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.